Physician

Alejandro R Calvo, MD

According to 2025 Medicare claims, Alejandro Calvo, MD (NPI: 1457341760) practices hematology/oncology in the Dayton-Kettering-Beavercreek, OH market, with the plurality of this provider's patient population coming from Montgomery, OH. This provider's primary affiliated billing organization is KETTERING INDEPENDENT MEDICAL GROUP INC (NPI: 1629387865; TIN: 27-2649285) and primary practice location at 45429-1265. Calvo is affiliated with the Kettering Physician Partners Accountable Care LLC (ACO ID: A5062), participating under the MSSP model.

Calvo's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 432 traditional Medicare patients, billed 1,555 HCPCS/CPT codes, and received $97,081 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 2,442 prescription claims across 364 beneficiaries totaling $6,401,931 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 57 claims. Open Payments data shows 81 records totaling $109,111. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing started with an early spike, then settled into a lower baseline, moving from $447,534 to $97,081. In contrast, Part D prescription costs have risen steadily, from $2,747,767 to $6,401,931. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $5,329 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	459	32,674	$447,534
2016	489	1,884	$148,543
2017	505	1,535	$149,475
2018	475	1,265	$125,543
2019	458	1,209	$123,165
2020	462	1,235	$107,341
2021	440	1,091	$114,257
2022	416	933	$91,997
2023	444	918	$98,614
2024	432	1,555	$97,081

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	273	2,030	$2,747,767
2016	273	1,826	$2,789,390
2017	287	1,980	$3,363,109
2018	281	2,089	$3,422,421
2019	266	1,918	$3,859,763
2020	316	2,111	$4,327,920
2021	315	2,026	$4,475,983
2022	299	1,925	$4,795,245
2023	299	2,010	$4,320,110
2024	364	2,442	$6,401,931

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	117	$27,486
2016	N/R	145	$17,812
2017	N/R	60	$10,017
2018	N/R	N/R	N/R
2019	N/R	68	$7,502
2020	N/R	82	$5,784
2021	N/R	108	$7,070
2022	N/R	78	$2,835
2023	N/R	57	$9,309
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	56	57	$125
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	42	42	$122
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	355	692	$97
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	50	98	$86
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	349	639	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	134	3,690	$2,028,904
Lenalidomide	Lenalidomide	44	1,211	$636,009
Verzenio	Abemaciclib	41	1,148	$630,765
Tagrisso	Osimertinib Mesylate	29	870	$476,564
Pomalyst	Pomalidomide	20	560	$404,823

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	79	$89,549	JAZZ PHARMACEUTICALS INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$19,562	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alejandro R. Calvo, MD?

Tedicare shows public-source Medicare data for Alejandro R. Calvo, MD (NPI 1457341760), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alejandro R. Calvo, MD have ACO affiliation data?

Alejandro R. Calvo, MD is shown with ACO affiliation data for Kettering Physician Partners Accountable Care LLC (MSSP, ACO ID A5062).

What billing organization is linked to Alejandro R. Calvo, MD?

Alejandro R. Calvo, MD is linked to KETTERING INDEPENDENT MEDICAL GROUP INC (billing NPI 1629387865) in the available physician profile data.

Does Alejandro R. Calvo, MD have Open Payments data?

Alejandro R. Calvo, MD has 81 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.